<PAGE>

UNITED STATES
                  SECURITIES AND EXCHANGE COMMISSION
                         Washington, D.C.  20549

                              FORM 10-Q/A

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

             For the quarterly period ended September 30, 2003

                                OR

[ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

            For the transition period from N/A to N/A
                                           ---    ---

                      Commission File No. 814-82

 TECHNOLOGY FUNDING VENTURE PARTNERS V, AN AGGRESSIVE GROWTH FUND, L.P.
 ----------------------------------------------------------------------
          (Exact name of Registrant as specified in its charter)

          Delaware                              94-3094910
-------------------------------     ----------------------------------
(State or other jurisdiction of    (I.R.S. Employer Identification No.)
incorporation or organization)

1107 Investment Blvd., Suite 180
El Dorado Hills, California                                       95762
---------------------------------------                       --------
(Address of principal executive offices)                     (Zip Code)

                              (916) 941-1400
                      -------------------------------
           (Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:  None
Securities registered pursuant to Section 12(g) of the Act:  Limited
Partnership Units

Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.   Yes X No
                                                    ---  ---

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12B-2 of the Act).                Yes    No X
                                                     ---   ---

No active market for the units of limited partnership interests ("Units")
exists, and therefore the market value of such Units cannot be determined.

Introduction
--------------------------

This First Amended Form 10Q is being filed because the individual capital
balances for both Limited Partners and General Partners were inaccurately
reported in the Partnership's prior quarterly filing for the period ended
September 30, 2003.  The correction is reflected in the accompanying
financial statements.

Forward-Looking Statements
--------------------------

The Private Securities Litigation Reform Act of 1995 (the Act) provides a
safe harbor for forward-looking statements made by or on behalf of the
Partnership.  The Partnership and its representatives may from time to time
make written or oral statements that are "forward-looking," including
statements contained in this report and other filings with the Securities and
Exchange Commission, and reports to the Partnership's shareholders and news
releases.  All statements that express expectations, estimates, forecasts and
projections are forward-looking statements within the meaning of the Act.  In
addition, other written or oral statements, which constitute forward-looking
statements, may be made by or on behalf of the Partnership.  Words such as
"expects," "anticipates," "intends," "plans," "believes," "seeks,"
"estimates," "projects," "forecasts," "may," "should," variations of such
words and similar expressions are intended to identify such forward-looking
statements.  These statements are not guarantees of future performance and
involve certain risks, uncertainties and assumptions, which are difficult to
predict.  Therefore, actual outcomes and results may differ materially from
what is expressed or forecasted in or suggested by such forward-looking
statements.  The Partnership undertakes no obligation to update publicly any
forward-looking statements, whether as a result of new information, future
events or otherwise.


<PAGE>
I.  FINANCIAL INFORMATION

Item 1.  Financial Statements

BALANCE SHEETS
--------------
<TABLE>
<CAPTION>
                                             (unaudited)
                                            September 30,     December 31,
                                                2003             2002
                                            -------------     ------------
<S>                                         <C>               <C>
ASSETS

Equity investments (cost of
 $16,387,499 and $21,605,935 at
 September 30, 2003, and December 31,
 2002, respectively)                         $13,614,159      $ 6,827,968
Notes receivable, net (cost of
 $297,254 and $184,293 at September 30,
 2003, and December 31, 2002,
 respectively)                                    79,682           36,858
                                              ----------       ----------
     Total investments                        13,693,841        6,864,826

Cash and cash equivalents                         22,697        1,749,984
Prepaid expenses                                 298,011          357,106
Other receivable                                   3,938          774,298
Other assets                                          --          194,690
                                              ----------       ----------
     Total assets                            $14,018,487      $ 9,940,904
                                              ==========       ==========



BALANCE SHEETS (unaudited) (continued)
-------------------------------------

LIABILITIES AND PARTNERS' CAPITAL

Accounts payable and accrued expenses        $    31,893      $    44,870
Due to related parties                           110,770           21,279
Other liabilities                                  1,240               --
                                              ----------       ----------
     Total liabilities                           143,903           66,149

Commitments and contingencies
 (See Note 8)

Partners' capital:
 Limited Partners
  (400,000 Units outstanding)                 13,868,899       13,305,996
 General Partners                                  5,685       (3,431,241)
                                              ----------       ----------
     Total partners' capital                  13,874,584        9,874,755
                                              ----------       ----------
     Total liabilities and partners'
      capital                                $14,018,487      $ 9,940,904
                                              ==========       ==========
</TABLE>





















See accompanying notes are an integral part of these financial statements.



STATEMENTS OF INVESTMENTS
-------------------------
<TABLE>
<CAPTION>
                                          Principal
                                          Amount or     September 30, 2003       December 31, 2002
Industry                                  Shares at     -----------------        -----------------
(1)                        Investment   September 30,   Cost        Fair         Cost        Fair
Company         Position      Date          2003        Basis       Value        Basis       Value
----------      --------   ----------   -----------     -----       -----        -----       -----
<S>                <C>       <C>      <C>          <C>         <C>           <C>         <C>

Equity Investments
------------------

Biomedical
----------
0.3% and 0.4% at September 30, 2003, and December 31, 2002, respectively
------------------------------------------------------------------------
Celera Genomics Group
 (formerly Axys
 Pharmaceuticals, Common
 Inc.)            shares      2000        4,065   $   141,000 $    47,520   $  141,000   $  38,821
                                                   ----------  ----------   ----------   ---------
                                                      141,000      47,520      141,000      38,821
                                                   ----------  ----------   ----------   ---------

Biotechnology
-------------
1.1% and 2.4% at September 30, 2003, and December 31, 2002, respectively
------------------------------------------------------------------------
CellzDirect, Inc. Preferred
  (a) (b)         shares      2002      970,761       375,000     150,000      375,001      75,000


STATEMENTS OF INVESTMENTS (continued)
------------------------------------
Hemoxymed, Inc.
 (formerly
 Molecular
 Geriatrics       Common
 Corporation)(a)  shares      1993       31,057       250,000       6,988      250,000       1,708
Prolinx, Inc.     Common      1995-
 (a) (b)          shares      2000           --            --          --    2,766,870      64,544
Prolinx, Inc.     Preferred   1995-
 (a) (b)          shares      2001           --            --          --      988,170      98,835
Prolinx, Inc.     Common and
 (a) (b)          Preferred share
                  warrants at
                  $.0001-$.90;
                  expiring    1998-
                  2004-2010   2001           --            --          --        6,061           0
                                                   ----------  ----------   ----------   ---------
                                                      625,000     156,988    4,386,102     240,087
                                                   ----------  ----------   ----------   ---------

Communications
--------------
1.8% and 1.6% at September 30, 2003, and December 31, 2002, respectively
------------------------------------------------------------------------
iVillage          Common      1996-
 Inc.             shares      2000       83,111       301,403     184,507      301,403      78,124
WorldRes.com,     Common      1997-
 Inc. (a) (b)     shares      2001      222,063     1,059,651      66,619    1,059,652      66,619
WorldRes.com,     Convertible
 Inc. (a) (b)     note (2)    2002     $136,000             0           0      144,965      14,497
                                                   ----------  ----------   ----------   ---------
                                                    1,361,054     251,126    1,506,020     159,240
                                                   ----------  ----------   ----------   ---------


STATEMENTS OF INVESTMENTS (continued)
------------------------------------

Environmental
-------------
0.0% and 0.0% at September 30, 2003, and December 31, 2002, respectively
------------------------------------------------------------------------
Triangle
 Biomedical
 Sciences,        Common
 Inc.(a)          shares      1999        1,806        35,560           0       35,560           0
Triangle          Common
 Biomedical       share warrants
 Sciences,        at $28.00;
 Inc.(a)          expiring
                  2009        1999        1,806         1,806           0        1,806           0
                                                   ----------  ----------   ----------   ---------
                                                       37,365           0       37,366           0
                                                   ----------  ----------   ----------   ---------

High Tech/Financial
-------------------
2.0% and 2.8% at September 30, 2003, and December 31, 2002, respectively
------------------------------------------------------------------------
VenCore Solutions
 LLC  (a) (b)     LLC Units   2002      625,000       625,000     250,000      625,000     250,000
VenCore Solutions LLC Unit
 LLC  (a) (b)     warrants
                  at $0.001;
                  expiring
                  2007        2002       62,500             0      24,975            0      24,975
                                                   ----------  ----------   ----------   ---------
                                                      625,000     274,975      625,000     274,975
                                                   ----------  ----------   ----------   ---------


STATEMENTS OF INVESTMENTS (continued)
------------------------------------

Industrial/Business Automation
------------------------------
4.7% and 6.5% at September 30, 2003, and December 31, 2002, respectively
------------------------------------------------------------------------
Innergy Power
 Corporation      Preferred   1995-
 (a) (b)          shares      2002      890,006     2,727,035     522,574    2,707,509     512,816
Innergy Power
 Corporation      Common      2001-
 (a) (b)          shares      2002       18,818         4,201           0        4,201           0
Innergy Power     Common and
 Corporation      Preferred share
  (a) (b)         warrants at
                  $.60-$12.50;
                  expiring    1997-
                  2003-2006   2001      518,427                         0        3,000           0
Innergy Power
 Corporation      Convertible
  (a) (b)         note (2)    2001     $246,032       246,031     123,017      250,952     125,476
                                                   ----------  ----------   ----------   ---------
                                                    2,977,267     645,591    2,965,662     638,292
                                                   ----------  ----------   ----------   ---------

Information Technology
----------------------
1.6% and 2.2% at September 30, 2003, and December 31, 2002, respectively
------------------------------------------------------------------------
KeyEye
 Communications,  Preferred
 Inc. (a) (b)     shares      2002    3,142,856       550,000     220,000      550,000     220,000


STATEMENTS OF INVESTMENTS (continued)
------------------------------------
Virage, Inc.      Common
                  shares      2002        1,428         1,660       1,542        1,660       1,001
                                                   ----------  ----------   ----------   ---------
                                                      551,660     221,542      551,660     221,001
                                                   ----------  ----------   ----------   ---------

Medical
-------
36.0% and 44.0% at September 30, 2003, and December 31, 2002, respectively
--------------------------------------------------------------------------
Acusphere, Inc.   Preferred   1995-
 (a)              shares      2002           --            --          --    1,014,615      78,444
Acusphere, Inc.   Convertible
 (a)              notes       2003           --            --          --           --          --
Acusphere, Inc.   Common      1995-
 (a)              shares      2002      181,683     1,725,613   1,780,493            -           -
Atherotech,       Preferred   2000-
 Inc. (a) (b)     shares      2002    1,055,372     2,724,822   1,882,784    2,724,822   2,824,175
CareCentric.
 Solutions,       Common
 Inc.             shares      1999       25,810       206,718      20,671      206,718      16,777
Endocare, Inc.    Common      1996-
 (b)              shares      1999       49,764       163,874     103,261      163,874      26,376
Impres Medical,   Preferred
 Inc.(a) (b)      shares      2002    1,071,429       742,500     450,000      742,500     450,000
Impres Medical,   Common share
 Inc.(a) (b)      warrants
                  at $1.00;
                  expiring
                  2007        2002      214,285         7,500           0        7,500           0
Impres Medical,   Convertible
 Inc.             notes       2003     $315,344       317,445     190,414            0           0

STATEMENTS OF INVESTMENTS (continued)
------------------------------------
Periodontix,      Preferred   1993-
 Inc.(a)          shares      1999           --            --          --      556,001           0
Periodontix,      Common share
 Inc.(a)          warrants
                  at $2.25;
                  expiring    1999-
                  2004-2006   2000           --            --          --            0           0
Periodontix,      Convertible 1999-
 Inc.(a)          notes (2)   2000           --            --          --      359,816       4,427
Pharmadigm,       Preferred   1993-
 Inc.(a) (b)      shares      2002      917,596     1,304,396      47,941    1,304,396     383,526
Pherin
 Pharmaceuticals, Preferred
 Inc.(a)          shares      1991           --            --          --      200,000     106,000
Physiometrix,     Common      1996-
 Inc.             shares      2000      139,769       285,023     349,423      285,023      76,873
Resolution
 Sciences
 Corporation      Preferred
 (a) (b)          shares      2000           --            --          --      970,000           0
Resolution
 Sciences
 Corporation      Convertible 2001-
 (a) (b)          note (2)    2002           --            --          --      215,804           0
Sanarus Medical,  Preferred
 Inc.(a) (b)      shares      1999      260,000       390,000      89,960      390,000     224,900
Valentis, Inc.    Common      1994-
                  shares      2002       23,866       908,970      76,610      908,970     157,515
                                                   ----------  ----------   ----------   ---------
                                                    8,776,861   4,991,557   10,050,039   4,349,013
                                                   ----------  ----------   ----------   ---------


STATEMENTS OF INVESTMENTS (continued)
------------------------------------

Microelectronics
----------------
50.0% and 7.1% at September 30, 2003, and December 31, 2002, respectively
-------------------------------------------------------------------------
Tessera
 Technologies,
 Inc. (formerly
 Tessera, Inc.)   Preferred
 (3) (a)          shares      1992           --            --          --      500,000     542,368
Tessera
 Technologies,
 Inc. (formerly
 Tessera, Inc.    Common
 (3) (a)          shares      1997           --            --          --       56,500     157,632
Tessera
 Technologies,
 Inc. (formerly
 Tessera, Inc.    Common
 (3) (a)          shares      2003      566,886       556,500   6,940,807           --          --
                                                   ----------  ----------   ----------   ---------
                                                      556,500   6,940,808      556,500     700,000
                                                   ----------  ----------   ----------   ---------

Venture Capital Limited Partnership Investments
-----------------------------------------------
0.6% and 2.1% at September 30, 2003, and December 31, 2002, respectively
------------------------------------------------------------------------
Capital Valley    Preferred
 Ventures (a)     shares        2002         --            --          --       48,254      14,476
Capital Valley
 Ventures (a)     LLC units     2002         --            --          --        2,540         762


STATEMENTS OF INVESTMENTS (continued)
------------------------------------
CVM Equity        Ltd.
 Fund IV, Ltd     Partnership
 (a)              interests  various   $150,000        76,436      38,218       76,436      38,218
El Dorado         Ltd.
 Ventures III,    Partnership
 L.P. (a)         interests  various   $250,000       212,460      11,998      212,460      24,739
O,W&W Pacrim      Ltd.
 Investments      Partnership
 Limited (a)      interests  various       $400         1,000         500        1,000         500
Spectrum Equity   Ltd.
 Investors,       Partnership
 L.P. (a)         interests  various   $500,000       398,082       9,429      398,082     103,937
Trinity Ventures  Ltd.
IV, L.P. (a)      Partnership
                  interests  various   $175,006        47,814      23,907       47,814      23,907
                                                   ----------  ----------   ----------   ---------
                                                      735,792      84,052      786,586     206,539
                                                   ----------  ----------   ----------   ---------
Total equity investments 96.3% and 69.1% at
 September 30, 2003, and December 31, 2002,
 respectively                                      16,387,499  13,614,159   21,605,935   6,827,968
                                                   ----------  ----------   ----------   ---------


Notes Receivable, Net
---------------------
Avalon Vision     Secured
 Solutions, Inc.  note, 16%,
                  due 2004    1999     $164,906       196,103      39,221      184,293      36,858
Capital Valley    Secured
 Ventures (a)     note, 4.28%
                  due 2013    2003     $100,000       101,151      40,461            0           0
                                                   ----------  ----------   ----------   ---------
                                                      297,254      79,682      184,293      36,858
                                                   ----------  ----------   ----------   ---------

Total notes receivable 0.6% and 0.4% at
 September 30, 2003, and December 31, 2002,
 respectively                                         297,254      79,682      184,293      36,858
                                                   ----------  ----------   ----------   ---------

Total investments 96.9% and 69.5% at
 September 30, 2003, and December 31, 2002,
 respectively                                     $16,684,753 $13,693,841  $21,790,228  $6,864,826
                                                   ==========  ==========   ==========   =========


STATEMENTS OF INVESTMENTS (continued)
------------------------------------

Legend and footnotes:

--  No investment held at end of period.

0   Investment active with a carrying value or fair value of zero.

(a) Equity security acquired in a private placement transaction; resale may be subject
    to certain selling restrictions.
(b) Portfolio company is an affiliate of the Partnership; resale may be subject to
    certain selling restrictions.

(1) Represents the total fair value of a particular industry segment as a percentage
    of partners' capital at 09/30/03 and 12/31/02.
(2) The Partnership has no income-producing equity investments except for convertible
    notes, which include accrued interest. Interest rates on such notes range from 8.0
    percent to 8.25 percent.
(3) The Partnership filed dissenters' rights for Tessera, Inc., in June, 2003. The fair
    value was reclassified as a receivable at June 30, 2003.  The Partnership dropped its
    claim prior to Tessera, Inc.'s initial public offering in November 2003, and the
    investment was reclassified as an equity investment at September 30, 2003.  See Note 4.

</TABLE>








The accompanying notes are an integral part of these financial statements.


<PAGE>

STATEMENTS OF OPERATIONS (unaudited)
-----------------------------------
<TABLE>
<CAPTION>
                                              For the Three Months           For the Nine Months
                                               Ended September 30,           Ended September 30,
                                            ------------------------        ----------------------
                                              2003            2002            2003          2002
                                            --------        --------        --------      --------
<S>                                        <C>           <C>              <C>         <C>
Investment income:
 Notes receivable interest                 $  41,036    $    24,170      $    98,475   $    72,492
 Short-term interest income                      369         11,565            5,386        58,568
                                            --------      ---------        ---------     ---------
   Total investment income                    41,405         35,735          103,861       131,060

Investment expenses:
 Management fees                              24,233         37,999           70,961       133,924
 Individual General Partners' compensation    10,000          3,500           30,003        17,500
 Investment operations                        79,239         63,071          372,366       367,814
 Administrative and investor services        321,435        263,033        1,539,891     1,663,171
 Professional fees                            84,964         17,104          214,051        94,142
 Computer services                            21,054         28,981           80,559       117,956
 Interest expense                                 --             --               --        13,035
                                           ---------      ---------       ----------     ---------
   Total investment expenses                 540,924        413,688        2,307,831     2,407,542
                                           ---------      ---------       ----------     ---------
Net investment loss                         (499,519)      (377,953)      (2,203,970)   (2,276,482)
                                           ---------      ---------       ----------     ---------


STATEMENTS OF OPERATIONS (unaudited)(continued)
----------------------------------------------

 Realized loss from investment
  write-offs                              (3,294,136)    (5,446,528)      (6,089,821)   (5,446,528)
 Net realized (loss) gain from sales
  of equity investments                           --             --               --       616,293
 Realized gain from venture capital
  limited partnership investments              1,986            494          115,249        27,832
                                           ---------      ---------       ----------     ---------
Net realized loss                         (3,292,150)    (5,446,034)      (5,974,572)   (4,802,403)
                                           ---------      ---------       ----------     ---------
 Decrease (increase) in unrealized
  depreciation:
   Equity investments                      8,174,654       (966,151)      12,004,626    (3,035,912)
   Notes receivable                          (66,010)     5,443,203          (70,137)    5,441,172
                                           ---------      ---------       ----------     ---------
Net decrease (increase) in
 unrealized depreciation                   8,108,644      4,477,052       11,934,489     2,405,260
                                           ---------      ---------       ----------     ---------

Other income                                  50,050             --          243,880       666,667
                                           ---------      ---------       ----------     ---------
Net increase (decrease) in partners'
 capital resulting from operations       $ 4,367,025    $(1,346,935)     $ 3,999,827   $(4,006,958)
                                           =========      =========       ==========     =========
Net increase (decrease) in partners'
 capital resulting from operations
 per Unit                                $      2.13    $     (3.34)     $      1.41   $     (9.92)
                                           =========      =========       ==========     =========
</TABLE>
See accompanying notes are an integral part of these financial statements.



<PAGE>
STATEMENTS OF CASH FLOWS (unaudited)
-----------------------------------
<TABLE>
<CAPTION>
                                              For the Nine Months
                                              Ended September 30,
                                       ---------------------------------
                                              2003              2002
                                           ---------         ---------
<S>                                      <C>                <C>
Net increase (decrease) in partners'
 capital resulting from operations       $ 3,999,827       $(4,006,958)

Adjustments to reconcile net
 decrease in partners' capital
 resulting from operations
 to net cash used by operating
 activities:
  Net realized gain from sales
   of equity investments                          --          (616,293)
  Realized gain from venture capital
   limited partnership investments          (115,249)          (27,338)
  Realized loss from investment
   write-offs                              6,089,821         5,446,528
  Net (decrease) increase in unrealized
   depreciation:
    Equity investments                   (12,004,626)        3,035,912
    Notes receivable                          70,137        (5,441,172)
  Increase in accrued interest on notes
   receivable                                (53,593)          (63,349)
  Decrease (increase) in other
   receivables                               770,359          (666,667)
  Decrease in prepaid expenses                59,095                --
  Decrease in accounts payable
   and accrued expenses                      (12,977)         (68,080)
  Increase (decrease) in due to related
   parties                                    89,492           (60,156)
  Other changes, net                         195,930           (23,465)
                                          ----------         ---------
Net cash used by operating activities       (911,784)       (2,491,038)
                                          ----------         ---------


STATEMENTS OF CASH FLOWS (unaudited) (continued)
-----------------------------------------------

Cash flows from investing activities:
 Proceeds from sales of equity
  investments                                     --         1,370,006
 Issue of secured notes receivable           (50,000)               --
 Purchase of equity investments           (1,016,753)       (2,064,161)
 Repayments of notes receivable              136,000                --
 Distributions from venture capital
  limited partnership investments            115,249            23,620
                                           ---------         ---------
  Net cash used by investing
   activities                               (815,504)         (670,535)
                                           ---------         ---------
Cash flows from financing activities:
 Repayment of short-term borrowings               --        (1,200,000)
                                           ---------         ---------
  Net cash used by financing activities           --        (1,200,000)
                                           ---------         ---------
Net decrease in cash and
 cash equivalents                         (1,727,287)       (4,362,067)

Cash and cash equivalents at
 beginning of year                         1,749,984         7,222,914
                                           ---------         ---------
Cash and cash equivalents
 at September 30                         $    22,697        $2,860,847
                                           =========         =========


</TABLE>












See accompanying notes are an integral part of these financial statements.




<PAGE>

NOTES TO FINANCIAL STATEMENTS (unaudited)
----------------------------------------

1.     Interim Financial Statements
       ----------------------------

The accompanying unaudited financial statements included herein have been
prepared in accordance with the requirements of Form 10-Q and, therefore, do
not include all information and footnotes, which would be presented, were
such financial statements prepared in accordance with generally accepted
accounting principles in the United States of America.  These statements
should be read in conjunction with the Annual Report on Form 10-K for the
year ended December 31, 2002.  In the opinion of the Managing General
Partners, the accompanying interim financial statements reflect all
adjustments necessary for the fair presentation of the financial position,
results of operations, and cash flows for the interim periods presented.
Allocation of income and loss to Limited and General Partners is based on
cumulative income and loss.  Adjustments, if any, are reflected in the
current quarter balances.  The results of operations for such interim periods
are not necessarily indicative of results of operations to be expected for
the full year.

2.     Provision for Income Taxes
       --------------------------

No provision for income taxes has been made by the Partnership, as the
Partnership is not directly subject to taxation.  The partners are to report
their respective shares of Partnership income or loss on their individual tax
returns.


The accompanying financial statements are prepared using accounting
principles generally accepted in the United States of America, which may not
equate to tax accounting.  The cost of investments on a tax basis at
September 30, 2003, and December 31, 2002, was $17,484,489 and $22,445,400,
respectively.  At September 30, 2003, and December 31, 2002, gross unrealized
depreciation on investments based on cost for federal income tax purposes was
as follows:

<TABLE>
<CAPTION>
                                      September 30,     December 31,
                                          2003             2002
                                      ------------      -----------
<S>                                  <C>               <C>
Unrealized appreciation              $  6,625,595      $    708,843
Unrealized depreciation               (10,249,574)      (16,289,355)
                                       ----------        ----------
Net unrealized depreciation          $ (3,623,979)     $(15,580,512)
                                       ==========        ==========
</TABLE>

3.     Related Party Transactions
       --------------------------

Related party costs are included in investment expenses shown on the
Statements of Operations.  Related party costs for the nine months ended
September 30, 2003 and 2002, were as follows:
<TABLE>
<CAPTION>
                                                      2003         2002
                                                    --------     --------
<S>                                               <C>          <C>
Management fees                                   $   70,961   $  133,924
Operating expenses reimbursed to related parties   1,903,645    1,912,139
Individual General Partners' compensation             30,003       17,500

</TABLE>

The Partnership reimburses the Managing General Partners for certain
operating expenses incurred in connection with the business of the
Partnership.  Reimbursable operating expenses paid by the Managing General
Partners include expenses (other than organizational and offering expenses
and general partner overhead) such as administrative and investor services,
investment operations, and computer services.  Prior to 2000, the Partnership
Agreement stated that the Partnership could not reimburse the Managing
General Partners for certain operational costs that aggregate more than 1
percent of total Limited Partner capital contributions.  On December 8, 2000,
the Limited Partners approved an amendment to the Partnership Agreement,
which removed the limit on reimbursement of operational costs effective
January 1, 2000.  Certain reimbursable expenses have been accrued based upon
interim estimates prepared by the Managing General Partners and are adjusted
to actual cost periodically.  There were $94,669 and $9,866 due to related
parties at September 30, 2003, and December 31, 2002, respectively, for such
reimbursable expenses.

Management fees due to the Managing General Partners were $16,102 and $11,413
at September 30, 2003, and December 31, 2002, respectively, and were included
in due to related parties.

Officers of the Managing General Partners occasionally receive stock options
as compensation for serving on the Boards of Directors of portfolio
companies.  It is the Managing General Partners' policy that all such
compensation be transferred to the investing partnerships.  If the options
are non-transferable, they are not recorded as an asset of the Partnership.
Any profit from the exercise of such options will be transferred if and when
the options are exercised and the underlying stock is sold by the officers.
Any such profit is allocated amongst the Partnership and affiliated
partnerships based upon their proportionate investments in the portfolio
company.  At September 30, 2003, the Partnership and affiliated partnerships
had an indirect interest in non-transferable Endocare, Inc., Sanarus Medical,
Inc. and Physiometrix, Inc. options with a fair value of $5,543.

Retention bonuses were offered to and accepted by key employees of the
Managing General Partners in late 2002.  The expense for these bonuses, which
were approved by the Independent General Partners during the September 2002
Individual General Partner meeting, was prepaid by the Partnership in October
and December 2002.  The amount of prepaid operating expenses was $371,570.
The bonuses, incremented by annual salary increases, will be paid to those
individuals who are still full-time employees of the Managing General
Partners in April 2007.  The expense for the bonus is recognized ratably over
the beneficial period, October 2002 to April 2007.  As of September 30, 2003,
the Partnership had recognized expense of $59,085. Upon the resignation of
personnel, no adjustment to the retention bonus amount previously paid by the
Partnership to the Managing General Partners shall occur until a replacement
person is hired.

4.     Equity Investments
       ------------------

All investments are valued at fair value as determined in good faith by the
Managing General Partners.


Marketable Equity Securities
----------------------------

At September 30, 2003, and December 31, 2002, marketable equity securities
had aggregate costs of $1,844,774 and aggregate market values of $677,152 and
$369,111, respectively.  The net unrealized losses at September 30, 2003, and
December 31, 2002, included gross gains of $93,673 and $22,809, respectively.

Restricted Securities
---------------------

At September 30, 2003, and December 31, 2002, restricted securities had
aggregate costs of $14,781,412 and $19,761,161, respectively, and aggregate
fair values of $5,001,039 and $6,458,857, respectively, representing 47.0
percent and 66.3 percent, respectively, of the net assets of the Partnership.

Significant purchases, sales and write-offs of equity investments during the
nine months ended September 30, 2003, were as follows:

Acusphere, Inc.
--------------

The Partnership funded convertible secured notes of $537,267 and $144,622 to
Acusphere, Inc. in April and June, 2003.  Both notes carry a rate of 10
percent and will mature in April and June, 2004, respectively.  See Note 5
for additional information on Acusphere.

Capital Valley Ventures
-----------------------

In September 2003, the Partnership issued a secured non-recourse promissory
note for $100,794 to the company with an interest rate of 4.25 percent.  The
note and accrued interest are due in September 2013.  A $50,794 equity
investment made in March 2002 was converted to debt and represents
approximately half of this note.

CareCentric Solutions, Inc.
---------------------------

On September 4, 2003, the company held a Special Meeting at which
shareholders approved a merger with an investor group that had the effect of
taking CareCentric private.  The company has ceased reporting as a public
company and its shares no longer trade on any exchange.  The Statement of
Investments for September 30, 2003, reflects the company's change in status.


Impres Medical, Inc.
--------------------

In August 2003, the Partnership issued a convertible note for $315,344 to the
company with an interest rate of 8 percent.

Innergy Power Corporation
-------------------------

In August 2003, the Partnership received 9,760 Series C Preferred shares in
lieu of $19,520 in accrued interest on a $244,000 promissory note due on
December 31, 2003.

Pherin Pharmaceuticals, Inc.
---------------------------

The Partnership wrote off its entire investment of $200,000 as of March 31,
2003, after Pherin Pharmaceuticals, Inc. ceased domestic operations. The
Partnership is not expecting any return on its investment.

Prolinx, Inc.
-------------

In March 2003, the Partnership wrote off its entire investment of $3,761,101
in Prolinx, Inc.  The company filed for Chapter 7 bankruptcy on March 27,
2003. There is no anticipated recovery for the shareholders.

Resolution Sciences Corporation
-------------------------------

During the quarter ended March 31, 2003, Resolution Sciences Corporation
filed for Chapter 7 bankruptcy and the investors will not realize any
recovery. Consequently, the Partnership wrote off its entire investment of
$1,185,804 as of March 31, 2003.

Tessera Technologies, Inc.(formerly Tessera, Inc.)
--------------------------------------------------

In January 2003, Tessera, Inc., closed a corporate reorganization under which
Tessera, Inc., became a wholly owned subsidiary of Tessera Technologies, Inc.
The reorganization was intended to position the company for an initial public
offering.  The dissenters' rights provision of the California General
Corporation Law allows any shareholder who does not wish to accept the
consideration offered through a merger to have the "fair market value" of
the investment determined by a state court.  The Partnership filed a
complaint claiming dissenters' rights against Tessera in May 2003.  At June
30, 2003, the Partnership recorded a receivable of $2,910,308 representing
the fair value of the dissenters' rights and the associated realized gain of
$2,353,809.  On September 4, 2003, Tessera Technologies, Inc. filed a
registration statement with the SEC for a public offering.  On September 25,
2003, the Partnership dropped its dissenters' claim after Tessera agreed to
allow the Partnership to participate in the offering on the same terms as its
other shareholders.  As a result, the Partnership's holdings reverted back to
shares.  Accordingly, the receivable recorded at June 30, 2003, was
reclassified as an equity investment, and the realized gain was reversed.
See Note 5 for additional information.

WorldRes.com, Inc.
------------------

During the third quarter of 2003, WorldRes.com, Inc. repaid a convertible
note issued by the Partnership.  The Partnership received $150,867, including
accrued interest on the note.

Other Equity Investments
------------------------

Other significant changes reflected in the Statements of Investments relate
to market value fluctuations for publicly traded portfolio companies or
changes in the fair value of private companies as determined in accordance
with the policy described in Note 1 to the financial statements included in
the Partnership's December 31, 2002, Form 10-K.

5.     Subsequent Events
       -----------------

On October 8, 2003, subsequent to the end of the third quarter, Acusphere,
Inc., a private company in the biotechnology industry, conducted an initial
public offering.  Prior to the offering, Acusphere shares were subject to a
reverse split, which converted the Partnership's 556,337 Preferred shares
into 181,683 common shares.  The offering priced at $14 per share.  The
Partnership's Acusphere shares are subject to a 180-day lock-up period.  The
reverse stock split is reflected in the Statement of Investments as of
September 30, 2003.

On November 13, 2003, subsequent to the end of the third quarter, Tessera
Technologies, Inc. (Tessera), a private company in the microelectronics
industry, conducted an initial public offering.  Prior to the offering, the
Partnership dropped its claim of dissenters' rights after Tessera agreed to
allow the Partnership to sell its shares in the offering at the offering
price.  The offering priced at $13 per share.  The Partnership sold all
566,886 of its shares at the offering price for net proceeds of $6,853,652.
The offering price is reflected in the fair value of Tessera on the Statement
of Investments as of September 30, 2003.

On November 21, 2003, a tax distribution was declared and paid to the General
Partners totaling $1,590,000.

6.     Notes Receivable
       ----------------

Activity from January 1 through September 30 consisted of:
<TABLE>
<CAPTION>
                                                 2003          2002
                                               --------      --------
<S>                                            <C>         <C>
Balance at January 1                           $ 36,858    $   86,920
Change in accrued interest receivable            12,167        10,712
Write-off of notes receivable and accrued
 interest                                            --    (5,446,528)
Net increase in unrealized depreciation
 of notes receivable                            (70,137)    5,441,172
                                                 ------     ---------
Balance at September 30                        $(21,112)   $   92,276
                                                 ======     =========
</TABLE>

The interest rate on the note receivable at September 30, 2003, was 16
percent.  The note is due in 2004.

7.     Cash and Cash Equivalents
       -------------------------

Cash and cash equivalents at September 30, 2003, and December 31, 2002,
consisted of:
<TABLE>
<CAPTION>
                                                  2003           2002
                                                --------       --------
<S>                                          <C>             <C>
Demand accounts                                 $ (6,244)    $  814,726
Money market accounts                             28,941        935,258
                                                 -------      ---------
 Total                                          $ 22,697     $1,749,984
                                                 =======      =========
</TABLE>

8.     Other Receivables
       -----------------

At June 30, 2003, other receivables included an advance made to Dakota
Holdings, LLC (DHL) (formerly Dakota Heritage, LLC).  On behalf of DHL, the
Partnership had advanced $16,241 to Dakota Arms, Inc. (DAI), a wholly owned
subsidiary of DHL.  Originally, the Partnership, an affiliated partnership
and an outside party planned to invest $50,000, $700,000 and $500,000,
respectively, in DHL.  Another affiliated partnership bought the
Partnership's receivable in August 2003 and repaid the advance.

9.     Commitments and Contingencies
       -----------------------------

From time to time, the Partnership is a party to financial instruments with
off-balance-sheet risk in the normal course of its business.  Generally,
these instruments are commitments for future equity fundings, venture capital
limited partnership investments, equipment financing commitments, or accounts
receivable lines of credit that are outstanding but not currently fully
utilized.  As they do not represent current outstanding balances, these
unfunded commitments are not recognized in the financial statements.  At
September 30, 2003, the Partnership had unfunded equity commitments of $0.

In October 2000, Kanematsu Corporation, a creditor of one of the
Partnership's portfolio companies, initiated an arbitration proceeding
against the Partnership, two affiliated partnerships and a fourth co-
investor.  Kanematsu was seeking to recover $2,000,000, the purchase price in
a contract by which the Partnership and the other entities were alleged to
have agreed to purchase certain debt securities of the portfolio company from
Kanematsu.  The Partnership and affiliated partnerships asserted
counterclaims against Kanematsu.  On February 12, 2002, the Partnership,
affiliated partnerships and the co-investor were awarded $4,000,000 and all
of Kanematsu's claims were denied.  The award is in full settlement of all
claims and counterclaims.  The Partnership recognized revenue and a
receivable of $666,667 as of February 12, 2002, for its proportionate share
of the award.  Kanematsu immediately filed a petition to vacate the award,
and on October 9, 2002, the United States District Court issued an order
confirming the arbitration award.  Kanematsu appealed the order but in early
November 2002 paid a forbearance fee of $200,000 in exchange for an option to
settle all liabilities.  On November 29, 2002, Kanematsu agreed to settle for
$3,999,999.  A decision on the allocation of the proceeds between the
Partnership, affiliates and co-investor was reached in January 2003; however,
a dispute regarding the legal fees arose.  The Partnership received $774,298
on February 13, 2003, which represented its proportionate share of the
settlement, less disputed legal fees, plus accrued interest.  The Partnership
recognized the additional revenue and receivable of $107,631 at December 31,
2002.  In March 2003, the law firm remitted $193,830, the remaining amount of
the award, to the Partnership.

From time to time, the Partnership is subject to routine litigation
incidental to the business of the Partnership.  Although there can be no
assurances as to the ultimate disposition of these matters and the proceeding
disclosed above, it is the opinion of the Managing General Partners, based
upon the information available at this time, that the expected outcome of
these matters, individually or in the aggregate, will not have a material
adverse effect on the results of operations and financial condition of the
Partnership.

10.    Financial Highlights
       --------------------
<TABLE>
<CAPTION>
                                                       For The Nine Months
                                                       Ended September 30,
                                                       -------------------
                                                          2003     2002
                                                         ------   ------
<S>                                                    <C>          <C>
(all amounts on a per Unit basis)
Net asset value, beginning of period                     $33.29   $35.75

(Loss) income from investment operations:
  Net investment loss                                     (0.72)   (3.98)
  Net realized and unrealized gain (loss) on investments   2.13    (5.94)
                                                          -----    -----
  Total from investment operations                         1.41    (9.92)
                                                          -----    -----
Net asset value, end of period                           $34.70   $25.83
                                                          =====    =====

Total return                                               4.23%  (27.74)%

Ratios to average net assets:
 Net investment loss                                      (2.13)% (12.94)%
 Expenses                                                 16.97%   19.55%

</TABLE>

Pursuant to the Partnership Agreement, net profit shall be allocated first to
those Partners with deficit capital account balances until such deficits have
been eliminated. The net asset values shown above assume the Partnership is
in liquidation.  Upon liquidation, the General Partners would contribute
capital equal to the amount of the Limited Partners' deficit.  Upon
liquidation, the General Partners would not be required to contribute cash to
the Partnership, as the net asset value is greater than the General Partners'
negative capital balance. Net asset value has been calculated in accordance
with this provision of the Partnership Agreement.

Item 2.  Management's Discussion and Analysis of Financial
         Condition and Results of Operations

Liquidity and Capital Resources
-------------------------------

The Partnership operates as a business development company under the
Investment Company Act of 1940 and makes venture capital investments in new
and developing companies.  The Partnership's financial condition is dependent
upon the success of the portfolio companies.  There is no ready market for
many of the Partnership's investments.  It is possible that some of its
venture capital investments may be a complete loss or may be unprofitable and
that others will appear likely to become successful, but may never realize
their potential.  The valuation of the Partnership's investments in
securities for which there are no available market quotes is subject to the
estimate of the Managing General Partners in accordance with the valuation
guidance described in Note 1 to the financial statements included in the
Partnership's December 31, 2002, Form 10-K.  In the absence of readily
obtainable market values, the estimated fair value of the Partnership's
investments may differ significantly from the values that would have been
used had a ready market existed.
During the nine months ended September 30, 2003, net cash used by operating
activities totaled $911,784.  The Partnership paid management fees of $55,609
to the Managing General Partners and reimbursed related parties for other
investment expenses of $1,574,480. In addition, $30,003 was paid to the
Individual General Partners as compensation for their services.  The
Partnership paid other investment expenses of $316,199. The Partnership
received interest income of $50,268 and other income of $1,014,240.
During the nine months ended September 30, 2003, there were no equity
investments funded.  At September 30, 2003, the Partnership had no
commitments to fund additional investments.

Cash and cash equivalents at September 30, 2003, were $22,697.  Cash
reserves, interest income on short-term investments and future proceeds from
investment sales are expected to be adequate to fund Partnership operations
through the next twelve months.

Results of Operations
---------------------

Current quarter compared to corresponding quarter in the preceding year
-----------------------------------------------------------------------

Net increase in partners' capital resulting from operations was $4,367,025
for the three months ended September 30, 2003, compared to a net decrease in
partners' capital resulting from operations of $1,346,935 for the same period
in 2002.

Realized loss from investment write-offs totaled $3,294,136 and $5,446,528
for the quarters ended September 30, 2003 and September 30, 2002,
respectively.  The 2003 write-off relates to a company in the medical
industry. The 2002 write-off related to notes and interest receivable from
Sutmyn Storage Corporation.  It had been determined by the Managing General
Partners that there would be no recovery on the notes after Sutmyn Storage
Corporation ceased operations; therefore, the cost of these notes was written
off.

During the quarter ended June 30, 2003, the Partnership recorded a gain of
$2,353,809 as a result of filing dissenters' rights.  On September 25, 2003,
the Partnership dropped its dissenters' claim after Tessera Technologies,
Inc. agreed to allow the Partnership to participate in its public offering on
the same terms as its other shareholders. (See Notes 4 and 5).  As a result
of the dismissal of the dissenters' rights claim, the Partnership reversed
the gain of $2,353,809 and reclassified the receivable associated with the
claim to an equity investment for the quarter ended September 30, 2003.

Net unrealized depreciation on equity investments was $8,174,654 and
$14,777,967 at September 30, 2003, and December 31, 2002, respectively.
During the quarter ended September 30, 2003, the Partnership recorded a
decrease in net unrealized depreciation on equity investments of $8,108,644.
During the quarter ended September 30, 2002, the Partnership recorded an
increase in net unrealized depreciation on equity investments of $966,151.
The increase in 2003 was primarily attributable to decreases in the fair
value of privately held companies in the medical industry. The change in 2002
was primarily attributable to a decrease in the publicly traded price of
Valentis, Inc. and decreases in the fair value of portfolio companies in the
medical industry and biotechnology industries.

Total investment expenses were $540,924 for the quarter ended September 30,
2003, compared to $413,688 for the same period in 2002. The increase was
primarily due to increased investment monitoring, administrative services and
professional fees.

During the quarter ended September 30, 2003, the Partnership recorded net
realized gains from venture capital limited partnership investments of
$1,986.  During the same period in 2002, there were gains of $494.

Given the inherent risk associated with the business of the Partnership, the
future performance of the portfolio company investments may significantly
impact future operations.

Current nine months compared to corresponding nine months in the preceding
--------------------------------------------------------------------------
year
----

Net increase in partners' capital resulting from operations was $3,999,827
for the nine months ended September 30, 2003, compared to a net decrease in
partners' capital resulting from operations of $4,006,958 for the same period
in 2002.

During the nine months ended September 30, 2003, the Partnership wrote off
its investments in Pherin Pharmaceuticals, Inc., Prolinx, Inc., Resolution
Sciences Corporation, Innergy Power Corporation and Periodontix, Inc.  These
totaled $200,000, $3,761,101, $1,188,393, $3,000 and $937,327, respectively.
During the same period in 2002, realized loss from investment write-offs
totaled $5,446,528 and related to notes and interest receivable from Sutmyn
Storage Corporation.  It had been determined by the Managing General Partners
that there would be no recovery on the notes after Sutmyn Storage Corporation
ceased operations; therefore, the cost of these notes was written off.

During the quarter ended June 30, 2003, the Partnership recorded a gain of
$2,353,809 as a result of filing dissenters' rights.  On September 25, 2003,
the Partnership dropped its dissenters' claim after Tessera Technologies,
Inc. agreed to allow the Partnership to participate in its public offering on
the same terms as its other shareholders. (See Notes 4 and 5).  As a result
of the dismissal of the dissenters' rights claim, the Partnership reversed
the gain of $2,353,809 and reclassified the receivable associated with the
claim to an equity investment for the quarter ended September 30, 2003.

Net unrealized depreciation on equity investments was $12,004,626 and
$14,777,967 at September 30, 2003, and December 31, 2002, respectively.
During the nine months ended September 30, 2003, the Partnership recorded a
decrease in net unrealized depreciation on equity investments of $11,934,489
compared to an increase in unrealized depreciation of $3,035,912 during 2002.
The decrease in depreciation in 2003 was primarily attributable to the write-
off of the Partnership's investments in Pherin Pharmaceuticals, Inc.,
Prolinx, Inc. and Resolution Sciences Corporation. The change in 2002 was
primarily attributable to a net decrease in the fair value of portfolio
companies in the medical and biotechnology industries.

Other income of $243,880 and $666,667 was recognized during the nine months
ended September 30, 2003 and 2002, respectively.  This was the result of a
settlement between Kanematsu Corporation, a creditor of one of the
Partnership's portfolio companies, and the Partnership. See Note 9.

For the nine months ended September 30, 2002, net realized gain from equity
investment sales of $616,293 was primarily related to the sale of Matrix
Pharmaceutical, Inc.  During the same period in 2003, there was no realized
gain.

Total investment expenses were $2,307,831 for the nine months ended September
30, 2003, compared to $2,407,542 for the same period in 2002.  The decrease
was primarily due to decreased management fees, administrative and computer
services, offset by increased professional fees related to the Kanematsu
legal proceeding.

During the nine months ended September 30, 2003, the Partnership recorded net
realized gains from venture capital limited partnership investments of
$115,249.  During the same period in 2002, there were gains of $27,832.

During the nine months ended September, 2003 and 2002, interest income was
$103,861 and $131,060, respectively.  The decrease was primarily the result
of reduced cash balances.

Given the inherent risk associated with the business of the Partnership, the
future performance of the portfolio company investments may significantly
impact future operations.

Item 3.   Procedures and Controls

The undersigned is responsible for establishing and maintaining disclosure
controls and procedures for Technology Funding Venture Partners V, An
Aggressive Growth Fund, L.P.  Such officer has concluded (based upon his
evaluation of these controls and procedures as of a date within 90 days of
the filing of this report) that Technology Funding Venture Partners V, An
Aggressive Growth Fund, L.P.'s disclosure controls and procedures are
effective to ensure that information required to be disclosed by Technology
Funding Venture Partners V, An Aggressive Growth Fund, L.P. in this report is
accumulated and communicated to Technology Funding Venture Partners V, An
Aggressive Growth Fund, L.P.'s management, including its principal executive
officers as appropriate, to allow timely decisions regarding required
disclosure.

The certifying officer also has indicated that there were no significant
changes in Technology Funding Venture Partners V, An Aggressive Growth Fund,
L.P.'s internal controls or other factors that could significantly affect
such controls subsequent to the date of their evaluation other than changes
needed to maintain adequate separation of duties and responsibilities of
personnel in the ordinary course of business, and there were no corrective
actions with regard to significant deficiencies and material weaknesses.

                              CERTIFICATION
                              -------------

I, Charles R. Kokesh, President, Chief Executive Officer, Chief Financial
Officer and Chairman of Technology Funding Inc. and Managing General
Partner of Technology Funding Ltd., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Technology Funding
Venture Partners V, An Aggressive Growth Fund, L.P.;
2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all
material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this
quarterly report;
4. I am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
registrant and I have:
a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant is made known to me by
others within the entity, particularly during the period in which this
quarterly report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days prior to the filing date of
this quarterly report (the Evaluation Date); and
c) presented in this quarterly report my conclusions about the
effectiveness of the disclosure controls and procedures based on my
evaluation as of the Evaluation Date;
5. I have disclosed, based on my most recent evaluation, to the registrant's
auditors and the audit committee of registrant's board of directors (or
persons performing the equivalent function):
a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to
record, process, summarize and report financial data and have
identified for the registrant's auditors any material weaknesses in
internal controls; and
b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
controls; and


6. I have indicated in this quarterly report whether or not there were
significant changes in internal controls or in other factors that could
significantly affect internal controls subsequent to the date of my most
recent evaluation, including any corrective actions with regard to
significant deficiencies and material weaknesses.

Date:  November 14, 2003   By:    /s/Charles R. Kokesh
                               --------------------------------
                                     Charles R. Kokesh
                                     President, Chief Executive
                                     Officer, Chief Financial
                                     Officer and Chairman of
                                     Technology Funding Inc. and
                                     Managing General Partner of
                                     Technology Funding Ltd.



II.  OTHER INFORMATION

Item 6.   Exhibits and Reports on Form 8-K

(a)  A report on Form 8-K was filed by the Partnership during the
quarter ended March 31, 2003. Pursuant to Article 6 of the Partnership
Agreement for Technology Funding Venture Partners V, An Aggressive
Growth Fund, L.P., the Partnership Agreement had been amended. The
corrected Amended and Restated Limited Partnership Agreement is included
in the 8-K filed on January 8, 2003.





<PAGE>



                              SIGNATURES
                              ----------

Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be
signed on its behalf by the undersigned, thereunto duly authorized.

                         TECHNOLOGY FUNDING VENTURE PARTNERS V,
                         AN AGGRESSIVE GROWTH FUND, L.P.

                           By:  TECHNOLOGY FUNDING INC.
                                TECHNOLOGY FUNDING LTD.
                                Managing General Partners




Date:  November 14, 2003    By: /s/Charles R. Kokesh
                                ---------------------
                                   Charles R. Kokesh
                                   President, Chief Executive Officer,
                                   Chief Financial Officer and
                                   Chairman of Technology Funding Inc.
                                   and Managing General Partner of
                                   Technology Funding Ltd.





                             CERTIFICATION
                             -------------

In connection with the Technology Funding Venture Partners V, An Aggressive
Growth Fund, L.P. (the Partnership) Quarterly Report on Form 10-Q for the
period ending September 30, 2003, as filed with the Securities and Exchange
Commission (the Report), I Charles, R. Kokesh, President, Chief Executive
Officer, Chief Financial Officer and Chairman of Technology Funding Inc.
and Managing General Partner of Technology Funding Ltd., certify, pursuant
to 18 U.S.C. Section 1350, as added Section 906 of the Sarbanes-Oxley Act
of 2002, that:

1. The Report fully complies with the requirements of Section 15(d) of
the Securities Exchange Act of 1934; and

2. To my knowledge, the information contained in the Report fairly
presents, in all material respects, the financial condition and
results of operations of the Partnership as of and for the period
covered by the Report.

Date:  November 14, 2003   By:    /s/Charles R. Kokesh
                               --------------------------------
                                     Charles R. Kokesh
                                     President, Chief Executive
                                     Officer, Chief Financial
                                     Officer and Chairman of
                                     Technology Funding Inc. and
                                     Managing General Partner of
                                     Technology Funding Ltd.

Technology Funding Venture Partners V, An Aggressive Growth Fund, L.P.
(a Delaware limited partnership)

Page 24 of 34